New York State Teachers Retirement System Increases Stock Holdings in Pfizer Inc. $PFE

New York State Teachers Retirement System increased its stake in Pfizer Inc. (NYSE:PFE) by 1.8% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,754,731 shares of the biopharmaceutical company’s stock after acquiring an additional 85,341 shares during the quarter. New York State Teachers Retirement System’s holdings in Pfizer were worth $121,151,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Curio Wealth LLC boosted its holdings in Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,098 shares during the last quarter. Bayforest Capital Ltd purchased a new stake in shares of Pfizer during the first quarter worth approximately $28,000. Harbor Asset Planning Inc. acquired a new position in Pfizer in the 2nd quarter valued at $29,000. Howard Hughes Medical Institute purchased a new position in Pfizer in the 2nd quarter valued at $30,000. Finally, Darwin Wealth Management LLC acquired a new stake in Pfizer during the 2nd quarter worth $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Up 0.7%

Shares of Pfizer stock opened at $25.48 on Friday. The stock has a 50 day moving average of $25.26 and a 200 day moving average of $24.95. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The firm has a market capitalization of $144.84 billion, a price-to-earnings ratio of 14.81 and a beta of 0.47. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.69.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. The company had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s payout ratio is 100.00%.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive Phase 3 data for a PADCEV + Keytruda bladder‑cancer combo bolsters Pfizer’s oncology franchise and revenue outlook; clinical validation can drive upside for PFE if regulatory and commercial plans follow. Pfizer, Astellas Report Positive Phase 3 Trial Results for PADCEV Combination in Bladder Cancer Treatment
• Positive Sentiment: Real‑world breast cancer study update signals Pfizer is pushing strategically in the HER2‑positive space — a reminder of ongoing pipeline commercialization opportunities beyond legacy products. Pfizer’s Real‑World Breast Cancer Study Signals Strategic Push in HER2-Positive Market
• Positive Sentiment: Coverage of Pfizer’s AI and precision‑oncology deals highlights a shift in the investment story toward higher‑growth, tech‑enabled oncology programs — can improve long‑term growth perception. How Pfizer’s AI and Precision Oncology Deals Have Changed Its Investment Story
• Positive Sentiment: Partnership with Gordian Bio to probe new obesity targets strengthens Pfizer’s exposure to the high‑growth weight‑loss drug market — a strategic priority highlighted in recent sector narratives. Pfizer partners Gordian Bio to probe new obesity targets
• Positive Sentiment: Broader healthcare sector rebound (VHT coverage) is attracting flows to undervalued pharma names like Pfizer, supporting multiple expansion and demand for dividend/defensive stocks. This ETF Is Proof That the Healthcare Rebound Is Real
• Neutral Sentiment: JPMorgan Healthcare Conference preview: JPM will likely produce company updates and M&A headlines that can move PFE intraday — a near‑term volatility catalyst but outcome‑dependent. Healthy Returns: What to expect from pharma at the JPM conference
• Neutral Sentiment: Unusual options flow: heavy activity in March PFE puts (March 20 $29 put highest Vol/OI) — could reflect hedging or directional bearish bets; watch open interest and dealer delta for short‑term price pressure. Unusual Options Activity in Pfizer: 2 Strategies Traders Are Jumping On
• Negative Sentiment: Analyst/retail pieces predicting other healthcare stocks will outperform Pfizer and commentary about a recent ~6% drop signal negative sentiment and may pressure PFE if doubts about growth persist. Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026 Pfizer’s Stock Just Dropped 6%. Can the Pharmaceutical Giant Bounce Back in 2026?

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on PFE. Wolfe Research set a $24.00 price target on shares of Pfizer and gave the stock an “underperform” rating in a research note on Wednesday, December 17th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. HSBC restated a “buy” rating and issued a $29.00 price target on shares of Pfizer in a research report on Wednesday, December 10th. Scotiabank began coverage on Pfizer in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price objective on the stock. Finally, Citigroup assumed coverage on Pfizer in a research note on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $27.88.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.